Women’s health remains a big area of unmet medical need and since women make up half the population, the commercial opportunity is enormous, but investment in therapeutics for women – whether for female-specific conditions like endometriosis and menopause or broader areas of health – continues to be underwhelming.
Momentum In Women’s Health, But Big Obstacles Too
Unmet Need In Space Was A Theme At J.P. Morgan
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
More from Women's Health
• By
Deal Snapshot: Cosette will acquire struggling Mayne Pharma for about $430m, thereby augmenting its women’s health and dermatology portfolio and enhancing commercial capabilities.
• By
Over 140 biopharma leaders share their views on developments to watch for in key therapeutic areas this year. Advances in multiple scientific fields are opening up new avenues for treatment.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.